India Rupee Plunge Boon For Most Domestic Pharma Firms, But Gains May Be Delayed
This article was originally published in PharmAsia News
The Indian rupee has played havoc with the country’s macroeconomic fundamentals and like in emerging markets such as Turkey, Brazil and Indonesia caused policymakers to carefully eye capital flows. But India’s unique position as a major drug manufacturer and exporter gives many of its companies the prospect of higher domestic earnings as sales are widely priced in dollars.
You may also be interested in...
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.
Prime Minister Narendra Modi’s government has decided to "comprehensively review" India's antiquated drug legislation to take into account the latest medical developments and improve safety, amid complaints about poor-quality manufacturing and products.